Lyra Therapeutics (LYRA) Net Shares Issued and Repurchased (2020 - 2025)

Lyra Therapeutics has reported Net Shares Issued and Repurchased for 6 years, with the latest figure at $57716.0 in Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased fell 97.78% year-over-year to $57716.0 in Q4 2025; TTM through Dec 2025 was $57716.0, a 97.78% decrease from a year earlier, with the FY2025 full-year figure at $57716.0, down 97.78% from the prior year.
• Net Shares Issued and Repurchased was $57716.0 for Q4 2025 at Lyra Therapeutics, down from $1.8 million in the prior quarter.
• The five-year high for Net Shares Issued and Repurchased was $2.8 million in Q4 2022, with the low at $57716.0 in Q4 2025.
• Average Net Shares Issued and Repurchased over 5 years is $1.5 million, with a median of $1.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Shares Issued and Repurchased surged 560.09% in 2022, then slumped 97.78% in 2025.
• Over 5 years, Net Shares Issued and Repurchased stood at $428500.0 in 2021, then soared by 560.09% to $2.8 million in 2022, then plunged by 34.22% to $1.9 million in 2023, then surged by 40.01% to $2.6 million in 2024, then plunged by 97.78% to $57716.0 in 2025.
• The last three Net Shares Issued and Repurchased figures came in at $57716.0 (Q4 2025), $1.8 million (Q1 2025), and $2.6 million (Q4 2024), per Business Quant data.